Suppositories Market Size, Growth, Share & Trends Analysis

Report Code PH 9446
Published in Jul, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Suppositories Market by Type (Urethral, Rectal, Vaginal), Base (Oleaginous, Aqueous, Emulsifying), Prescription (OTC, Prescribed), Application (Analgesic, Laxatives, Anti-fungal, Nasal Decongestants), Patient (Adult & Pediatrics) - Global Forecast to 2030

Suppositories Market Size, Growth Drivers & Restraints

The global suppositories market, valued at US$1.56 billion in 2024, stood at US$1.63 billion in 2025 and is projected to advance at a resilient CAGR of 4.7% from 2025 to 2030, culminating in a forecasted valuation of US$2.05 billion by the end of the period. The growth in the suppositories market can be attributed to several critical factors. The rising prevalence of chronic conditions, particularly inflammatory bowel diseases (IBD), gastrointestinal diseases, and constipation, is a significant driver for the market. Additionally, growing demand for localized and targeted drug delivery for the treatment of hemorrhoids, and vaginal infections further support their market growth. Suppositories are mainly preferred for geriatrics and pediatrics who struggle with swallowing medicines. This demographic factor maintains continuous demand for suppositories, thereby driving their market growth. However, the availability of alternative therapies such as oral sustained-release tablets, long-acting injectables, and transdermal patches hinders market growth.

Suppositories Market – Global Forecast and Key Opportunities to 2030

Attractive Opportunities in the Suppositories Market

North America

Market growth in North America can be attributed to the rising geriatric population and chronic diseases such as constipation, inflammatory bowel diseases (IBD), and gynecological infections.

Market growth can be attributed to the increasing prevalence of chronic diseases, innovations in suppository base formulations, and the demand for targeted drug delivery solutions.

Increased preference of patient convivence pharmaceutical solutions, rising aging population, and growing opportunities in emerging economies are likely to promote significant growth opportunity of the market

North America dominates the suppositories market. This market is projected to reach USD 1.11 billion by 2030, at a CAGR of 4.8% during the forecast period.

The Asia Pacific is the fastest-growing regional market for suppositories, with China and India emerging as major growth hotspots. North America is the largest regional market for suppositories market, among which the US is the fastest growing.

Global Suppositories Market Dynamics

DRIVER: Increasing prevalence of chronic diseases

The growing prevalence of chronic diseases, such as inflammatory bowel diseases (IBD), gastrointestinal diseases, and constipation, is becoming the primary reason contributing the global suppository market growth. Functional constipation is a global health burden, especially among children and the aging population. Rectal suppositories such as glycerin or bisacodyl suppositories are the most commonly used suppositories for constipation treatment, where oral laxatives are not tolerable by pediatric and geriatric patients. Additionally, there is a global rise in inflammatory bowel diseases (IBD), which increasingly demand rectal suppositories, such as mesalamine and corticosteroid suppositories, to treat inflammation with minimal systemic side effects.

Furthermore, the growing vaginal infections like bacterial vaginosis and candidiasis continuously demand vaginal suppositories as key treatment options that contain antifungal and antibacterial properties. Therefore, all the above factors are sustaining steady need for rectal and vaginal suppositories, thereby driving overall market growth.

RESTRAINT: Availability of alternative drug delivery therapies

The increasing varieties of drug delivery methods tend to hinder the acceptability of suppositories globally. The major advantages that are promoted for suppositories are targeted drug delivery and reduced systemic side effects. However, they are often considered inferior due to the patient inconvenience and discomfort as compared to oral sustained-release tablets, transdermal patches, and long-acting injectable products. The oral drug tablets with controlled or extended-release formulations can steadily deliver drugs over a certain period, giving the drug the sustained effect of the suppository without the discomfort or insertion required. Similarly, widely used transdermal patch interventions in pain and hormone therapies bypass the gastrointestinal tract while permitting steady systemic absorption of the drug, which is already considered an advantage of suppositories. On the other hand, long-acting injectable formulations offer therapeutic coverage for months, so daily or repeated administration is less frequent compared to suppositories.

All these alternative trends of drug delivery therapies have deprived the prescription of suppositories, thereby hindering the market growth.

 

OPPORTUNITY: High growth opportunities in emerging markets

The recent innovations in technology relating to drug formulations are creating significant opportunities in the growth of the global suppository market. These innovations in suppository bases address the problems associated with the poor solubility of active pharmaceutical ingredients (APIs) and lower patient acceptability. Traditional suppositories are usually confronted with low bioavailability, while new techniques, including nanostructured lipid carriers (NLCs) and other nanotechnologies for drug delivery, drastically improve the formulation and absorption of poorly soluble drugs. These systems augment dissolution by increasing the surface area of the drug, thereby increasing absorption and enhancing the efficacy of treatment for conditions that remain untreated by this route. Additionally, 3D printing technologies have further supported pharmaceutical manufacturing, offering exact control over the size, shape, and drug-release profiles of suppositories. This customization is a boon for personalized medicine, and thus, the healthcare professionals can choose better treatment options for the patient's specific conditions. Together, nanotechnology and 3D printing expand the application to new therapeutic areas, thereby driving innovation and growth in the market.

CHALLENGES: Limited shelf life of suppositories

Unlike more stable dosage forms like tablets or capsules, suppositories typically contain components that are very sensitive to factors such as heat, moisture, and light, and this may result in melting, a loss of potency, or chemical degradation, unless the product is maintained under strictly monitored temperature conditions. Commercially prepared hormone-based suppositories or suppository dosage forms prepared from extracts of naturally derived anti-inflammatories represent a significant challenge, as they are very susceptible to degradation, such as oxidation and hydrolysis, which can occur with great speed and therefore have a relatively short shelf life. Thus, the inherent sensitivity of suppositories requires a secure cold chain to address all areas from the time of manufacture until the time of delivery, but not all product locations can sustain cold storage logistics, particularly in resource-limited areas, due to rising expenses. Therefore, all these factors will remain major barriers to the adoption and market growth of suppositories globally.

Global Suppositories Market Ecosystem Analysis

The suppositories market ecosystem comprises a network of pharmaceutical manufacturers, healthcare companies, and regulatory authorities working together to ensure the safe and effective development, distribution, and regulation of suppositories globally. Key players in this ecosystem are Bayer AG (Germany), Novartis AG (Switzerland), Sanofi (France), Zydus Group (India), Bliss GVS Pharma Limited (India), Church & Dwight Co., Inc. (US), Bausch Health Companies Inc. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), and Sun Pharmaceutical Industries Ltd. (India). These companies are involved in the formulation, manufacturing, and marketing of various suppository types like rectal, vaginal, and urethral.

The regulatory bodies play a vital role in maintaining the safety and quality standards of the suppositories. Agencies such as the US FDA, European Medicines Agency (EMA), UK’s MHRA, Australia’s TGA, and India’s CDSCO provide strict guidelines on suppository formulation, packaging (especially for thermosensitive products), and storage conditions. These agencies evaluate product efficacy, mandate clinical data, and regulate post-market surveillance. Together, this interconnected ecosystem ensures that suppositories meet high therapeutic standards while surpassing challenges such as cold-chain logistics and patient adherence.

Suppositories Market Ecosystem
 

The rectal segment held the largest market share in 2024.

The suppositories market, by type is divided into three main segments: rectal, vaginal, and urethral. Within this market, the rectal segment holds a larger share due to its wide range of therapeutic applications. The rectal suppositories are mostly used in the treatment of fever, pain, inflammation, constipation (e.g., paracetamol, diclofenac), and inflammatory bowel diseases (e.g., mesalamine). Moreover, the rectal suppositories are particularly prescribed for pediatric and geriatric patients, where oral administration may not be feasible due to swallowing difficulties, nausea, and sometimes unconsciousness. Furthermore, the convenience of these suppositories and their pharmacokinetic effect of bypassing first-pass metabolism and providing targeted drug delivery action further drives the segmental growth. Additionally, the increasing prevalence of gastrointestinal diseases contributes significantly to the market growth.

The prescribed suppositories segment accounted for the largest share in the suppositories market, by prescription type.

The prescribed suppositories segment held the largest market share attributed to the widespread clinical use of suppository dosage forms in managing acute and chronic conditions requiring physician consultation. Prescribed suppositories are often formulated with potent active pharmaceutical ingredients such as corticosteroids, artesunate, diazepam, and mesalamine, which require exact dosing. These factors drive the segmental growth of prescribed suppositories. Furthermore, regulatory guidelines in major markets such as the US, Europe, and India state that many suppository treatments, especially those with systemic effects, cannot be sold over-the-counter (OTC) without a physician's prescription. Additionally, the growing prevalence of chronic disorders coupled with physicians' preference for localized drug delivery methods further fuels the growth of the prescription segment.

North America accounted for the largest market share in 2024.

North America is poised to lead the suppositories market during the forecast period, driven by several pivotal factors. Th increasing prevalence of chronic diseases, aging population and increasing public health awareness programs are key contributors to this anticipated growth. The region's healthcare expenditure per capita, along with improved affordability, further enhances the market dynamics.

Prominent companies, including Church & Dwight Co., Inc. (US), Bausch Health Companies Inc. (Canada), and Prestige Consumer Healthcare (US), are fostering a culture of innovation within well-established research environments across the US and Canada. Their contributions to advancing formulation in suppositories are significant. Furthermore, the robust healthcare infrastructure in North America ensures the prompt deployment and integration of these advanced medical technologies. Compounding this growth is the demographic shift towards an aging population, which correlates with an increased prevalence of chronic illnesses, thereby heightening the demand for effective pharmaceutical drug delivery solutions. Collectively, these factors underscore a sustained and escalating need for suppositories across the region.

LARGEST SHARE (2024)
US FASTEST GROWING MARKET IN THE REGION
Suppositories Market Region

Recent Developments of Suppositories Market

  • In October 2024, Sanofi partnered with Opella to form an independent Consumer Healthcare company through a 50:50 joint venture with Clayton, Dubilier & Rice (CD&R). The new entity, Opella Healthcare Group, will allow more focused growth of OTC brands like Dulcoflex, while Sanofi will retain a 48.2% stake, enabling strategic oversight while allowing Opella full operational independence.
  • In January 2024, Sun Pharmaceutical Industries Ltd., acquired all outstanding ordinary shares of Taro Pharmaceutical (Israel). This acquisition helped Sun Pharma to expand its OTC portfolio and geographical presence.
  • In May 2023, Bayer expanded a new business unit in the United States, focused on developing precision health consumer products. This initiative aimed to leverage data science, genetics, and digital technologies to create personalized, science-based solutions in areas such as pain management, digestive health, and dermatology, reinforcing Bayer’s leadership in the self-care market.
  • In August 2023, Zydus Group received US FDA approval for its Indomethacin Suppositories (25 mg), including Competitive Generic Therapy (CGT) designation, signifying its first generic approval for this product. This approval strengthens Zydus’ US portfolio, reinforcing its presence in niche and specialized drug segments.

Key Market Players

Scope of the Report

Report Metric Details
Market size available for years 2023-2030
Base Year Considered 2024
Forecast period 2025-2030
Forecast units Value (USD Million/Billion)
Segments covered Type, base, prescription, application, patient type, and region
Geographies covered North America (US and Canada), Europe (Germany, UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, Australia, South Korea, India, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa [GCC Countries (UAE, Kingdom of Saudi Arabia, Rest of GCC countries), and Rest of Middle East & Africa

Key Questions Addressed by the Report

What are the drivers for the suppositories market?

The increasing incidence of inflammatory bowel diseases (IBD), the growing geriatric population, and innovation in suppository-based formulations are expected to drive market growth during the forecast period.

Which type of segment of the suppositories market witnesses the highest market share?

The rectal suppositories segment is expected to register the highest growth due to their wide use in pediatric, geriatric, and palliative care settings. Their ability to bypass first-pass metabolism and provide direct site action further supports market expansion.

Which application segment is expected to show strong growth?

The analgesic and antipyretic segment is expected to show significant growth, driven by the rising incidence of gastrointestinal diseases and the increasing geriatric and pediatric populations prone to fever and pain.

What are the main companies present in this market?

Major players include Bayer AG (Germany), Novartis AG (Switzerland), Sanofi (France), Zydus Group (India), Bliss GVS Pharma Limited (India), Church & Dwight Co., Inc. (US), Bausch Health Companies Inc. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Ltd. (India), Adcock Ingram (South Africa), Aspen Holdings (South Africa), Julphar (UAE), Cipla (India), Haleon Group of Companies (UK), and Prestige Consumer Healthcare (US).

Which region is expected to witness significant demand for the suppositories market in the coming years?

The Asia Pacific region is expected to see the fastest growth in suppository demand, particularly in China and India. This is due to the increasing prevalence of chronic diseases, expanding healthcare infrastructure, greater awareness of women’s health, and an emphasis on patient convenience.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Suppositories Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
25
RESEARCH METHODOLOGY
30
EXECUTIVE SUMMARY
42
PREMIUM INSIGHTS
46
MARKET OVERVIEW
50
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing prevalence of acute and chronic disorders
    - Booming geriatric population worldwide
    - Pharmacokinetic advantages of suppositories
    - Growing demand for targeted and localized drug delivery solutions
    RESTRAINTS
    - Stringent regulatory requirements
    - Rapid development of innovative drug delivery technologies
    - Low patient and caregiver acceptance
    OPPORTUNITIES
    - Emerging formulations and 3D techniques
    - Expanding therapeutic applications
    CHALLENGES
    - Complex formulation and drug delivery
    - Limited shelf life of suppositories
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND, BY KEY PLAYER
    AVERAGE SELLING PRICE TREND, BY REGION
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
  • 5.7 INVESTMENT AND FUNDING SCENARIO
  • 5.8 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - 3D printed multi-drug-loaded suppositories
    - Self-microemulsifying suppository systems
    COMPLEMENTARY TECHNOLOGIES
    - Mucoadhesive and bioadhesive polymers
    ADJACENT TECHNOLOGIES
    - Form-fill-seal (FFS) machine technology
  • 5.9 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR SUPPOSITORIES
    JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.10 TRADE ANALYSIS
    IMPORT DATA
    EXPORT DATA
  • 5.11 KEY CONFERENCES AND EVENTS, 2025–2026
  • 5.12 REGULATORY LANDSCAPE
    REGULATORY FRAMEWORK
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Middle East & Africa
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.13 PORTER’S FIVE FORCES ANALYSIS
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA
  • 5.15 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.16 IMPACT OF AI/GEN AI
    INTRODUCTION
    MARKET POTENTIAL OF AI ON SUPPOSITORIES MARKET
    AI USE CASES
    FUTURE OF GENERATIVE AI IN SUPPOSITORIES MARKET
  • 5.17 IMPACT OF 2025 US TARIFF
    INTRODUCTION
    KEY TARIFF RATES
    PRICE IMPACT ANALYSIS
    IMPACT ON COUNTRY/REGION
    IMPACT ON END-USER INDUSTRIES
SUPPOSITORIES MARKET, BY TYPE
86
  • 6.1 INTRODUCTION
  • 6.2 RECTAL SUPPOSITORIES
    EASE OF USE, AFFORDABILITY, AND QUICK RELIEF TO PROMOTE GROWTH
  • 6.3 VAGINAL SUPPOSITORIES
    SHORT-TERM THERAPY AND QUICK SYMPTOM RELIEF TO AUGMENT GROWTH
  • 6.4 URETHRAL SUPPOSITORIES
    NEED FOR LOCALIZED, FAST-ACTING THERAPY TO CONTRIBUTE TO GROWTH
SUPPOSITORIES MARKET, BY BASE
94
  • 7.1 INTRODUCTION
  • 7.2 OLEAGINOUS/ LIPOPHILIC BASES
    RISING PATIENT PREFERENCE FOR EASY-TO-USE, NON-ORAL DOSAGE FORMS TO FACILITATE GROWTH
  • 7.3 AQUEOUS/HYDROPHILIC BASES
    NEED TO MAINTAIN DRUG STABILITY TO SPUR GROWTH
  • 7.4 EMULSIFYING BASES
    CONSISTENT DRUG RELEASE AND ABSORPTION TO BOLSTER GROWTH
SUPPOSITORIES MARKET, BY PRESCRIPTION
100
  • 8.1 INTRODUCTION
  • 8.2 PRESCRIBED SUPPOSITORIES
    INCREASED RELIANCE ON PRESCRIPTION SUPPOSITORIES FOR HORMONE REPLACEMENT AND ANTIEMETIC TREATMENT TO SUPPORT GROWTH
  • 8.3 OVER-THE-COUNTER SUPPOSITORIES
    GROWING PREFERENCE FOR CONVENIENT, NON-INVASIVE RELIEF FROM COMMON HEALTH CONCERNS TO FUEL MARKET
SUPPOSITORIES MARKET, BY APPLICATION
105
  • 9.1 INTRODUCTION
  • 9.2 HEMORRHOID TREATMENTS
    INCREASING OBESITY AND SEDENTARY LIFESTYLE TO EXPEDITE GROWTH
  • 9.3 ANTI-BACTERIAL AND ANTI-FUNGAL APPLICATIONS
    GROWING BURDEN OF VAGINAL INFECTIONS TO PROPEL MARKET
  • 9.4 ANALGESICS & ANTIPYRETICS
    INCREASING INCIDENCE OF CHRONIC PAIN CONDITIONS TO ACCELERATE GROWTH
  • 9.5 LAXATIVES
    LOW DIETARY FIBER INTAKE AND RISING PREVALENCE OF CONSTIPATION TO BOOST MARKET
  • 9.6 ANTI-EMETICS
    GROWING USE OF ANTI-EMETIC SUPPOSITORIES FOR CHEMOTHERAPY, RADIATION THERAPY, OR POST-OPERATIVE RECOVERY TO DRIVE MARKET
  • 9.7 OTHER APPLICATIONS
SUPPOSITORIES MARKET, BY PATIENT TYPE
115
  • 10.1 INTRODUCTION
  • 10.2 ADULT PATIENTS
    GROWING FOCUS ON CHRONIC CONDITION MANAGEMENT TO DRIVE MARKET
  • 10.3 PEDIATRIC PATIENTS
    INCREASING NEED FOR ALTERNATIVE DRUG DELIVERY TO SUPPORT GROWTH
  • 10.4 GERIATRIC PATIENTS
    NEED FOR RELIABLE, EFFECTIVE, AND WELL-TOLERATED DRUG DELIVERY IN ELDERLY PATIENTS TO AID GROWTH
SUPPOSITORIES MARKET, BY REGION
121
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Rising demand for non-oral therapeutics among aging and chronic patient groups to augment growth
    CANADA
    - Government support and public health campaigns to encourage growth
  • 11.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - High healthcare spending and prescription culture to support growth
    FRANCE
    - Increasing use of suppositories in pediatrics, gynecology, and internal medicine to propel market
    UK
    - Growing use of suppositories for pediatric fever, antiemetic needs, and constipation management to drive market
    ITALY
    - Increasing pediatric patient population to contribute to growth
    SPAIN
    - Rising adoption of non-invasive, self-administered dosage forms to spur growth
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    JAPAN
    - Geriatric population and regulatory guidelines to drive market
    CHINA
    - Expanding elderly population to boost market
    INDIA
    - Increasing healthcare penetration across urban and semi-urban areas to promote growth
    AUSTRALIA
    - Increased patient volume and favorable government initiatives to sustain growth
    SOUTH KOREA
    - Favorable insurance policy to accelerate growth
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Expanding public healthcare access and domestic manufacturing to bolster growth
    MEXICO
    - Growing consumer preference for self-medication to propel market
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    GCC COUNTRIES
    - Kingdom of Saudi Arabia (KSA)
    - United Arab Emirates (UAE)
    - Rest of GCC Countries
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
189
  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SUPPOSITORIES MARKET
  • 12.3 REVENUE ANALYSIS, 2022–2024
  • 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.5 BRAND/PRODUCT COMPARISON
  • 12.6 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - Company footprint
    - Region footprint
    - Type footprint
    - Base footprint
    - Prescription footprint
  • 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of key startups/SMEs
  • 12.9 COMPETITIVE SCENARIO
    PRODUCT APPROVALS
    DEALS
    EXPANSIONS
COMPANY PROFILES
207
  • 13.1 KEY PLAYERS
    SANDOZ GROUP AG
    - Business overview
    - Products offered
    - MnM view
    TEVA PHARMACEUTICAL INDUSTRIES LTD.
    - Business overview
    - Products offered
    - MnM view
    CIPLA
    - Business overview
    - Products offered
    - MnM view
    SANOFI
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    SUN PHARMACEUTICAL INDUSTRIES LTD.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    BAYER AG
    - Business overview
    - Products offered
    - Recent developments
    NOVARTIS AG
    - Business overview
    - Products offered
    - Recent developments
    ZYDUS GROUP
    - Business overview
    - Products offered
    - Recent developments
    BLISS?GVS PHARMA LIMITED
    - Business overview
    - Products offered
    CHURCH & DWIGHT CO., INC.
    - Business overview
    - Products offered
    BAUSCH HEALTH COMPANIES INC.
    - Business overview
    - Products offered
    ADCOCK INGRAM
    - Business overview
    - Products offered
    ASPEN HOLDINGS
    - Business overview
    - Products offered
    JULPHAR
    - Business overview
    - Products offered
    HALEON GROUP OF COMPANIES
    - Business overview
    - Products offered
    LES LABORATOIRES SERVIER
    - Business overview
    - Products offered
    PRESTIGE CONSUMER HEALTHCARE INC.
    - Business overview
    - Products offered
    VIATRIS INC.
    - Business overview
    - Products offered
    GALEN LIMITED
    - Business overview
    - Products offered
    MERIDIAN ENTERPRISES PVT. LTD.
    - Business overview
    - Products offered
  • 13.2 OTHER PLAYERS
    COSETTE PHARMACEUTICALS
    FLAGSHIP
    OUBARI PHARMA
    LAVINA PHARMACEUTICALS PVT. LTD.
    NORWELL
APPENDIX
264
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 SUPPOSITORIES MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021–2024
  • TABLE 3 SUPPOSITORIES MARKET: RESEARCH ASSUMPTIONS
  • TABLE 4 SUPPOSITORIES MARKET: RISK ANALYSIS
  • TABLE 5 AVERAGE SELLING PRICE TREND OF RECTAL SUPPOSITORIES, BY KEY PLAYER, 2023–2025 (USD)
  • TABLE 6 AVERAGE SELLING PRICE TREND OF RECTAL SUPPOSITORIES, BY REGION, 2023–2025 (USD)
  • TABLE 7 SUPPOSITORIES MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 8 SUPPOSITORIES MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023–2025
  • TABLE 9 IMPORT DATA FOR HS CODE 3006, BY COUNTRY, 2021–2024 (USD THOUSAND)
  • TABLE 10 EXPORT DATA FOR HS CODE 3006, BY COUNTRY, 2021–2024 (USD THOUSAND)
  • TABLE 11 SUPPOSITORIES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
  • TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 SUPPOSITORIES MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%)
  • TABLE 19 KEY BUYING CRITERIA, BY TYPE
  • TABLE 20 SUPPOSITORIES MARKET: CURRENT UNMET NEEDS
  • TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 22 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR SUPPOSITORIES
  • TABLE 23 IMPACT ON COUNTRY/ REGION DUE TO US TARIFFS
  • TABLE 24 SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 25 KEY PLAYERS PROVIDING RECTAL SUPPOSITORIES
  • TABLE 26 RECTAL SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 27 KEY PLAYERS PROVIDING VAGINAL SUPPOSITORIES
  • TABLE 28 VAGINAL SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 29 KEY PLAYERS PROVIDING URETHRAL SUPPOSITORIES
  • TABLE 30 URETHRAL SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 31 SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 32 SUPPOSITORIES MARKET FOR OLEAGINOUS/LIPOPHILIC BASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 33 SUPPOSITORIES MARKET FOR AQUEOUS/HYDROPHILIC BASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 34 SUPPOSITORIES MARKET FOR EMULSIFYING BASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 35 SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 36 KEY PLAYERS PROVIDING PRESCRIBED SUPPOSITORIES
  • TABLE 37 PRESCRIBED SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 38 KEY PLAYERS PROVIDING OVER-THE-COUNTER (OTC) SUPPOSITORIES
  • TABLE 39 OVER-THE-COUNTER (OTC) SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 40 SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 41 SUPPOSITORIES MARKET FOR HEMORRHOID TREATMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 42 SUPPOSITORIES MARKET FOR ANTI-BACTERIAL & ANTI-FUNGAL APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 43 SUPPOSITORIES MARKET FOR ANALGESICS & ANTIPYRETICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 44 SUPPOSITORIES MARKET FOR LAXATIVES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 45 SUPPOSITORIES MARKET FOR ANTI-EMETICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 46 SUPPOSITORIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 47 SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 48 SUPPOSITORIES MARKET FOR ADULT PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 49 SUPPOSITORIES MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 50 SUPPOSITORIES MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 51 SUPPOSITORIES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 52 SUPPOSITORIES MARKET FOR PRESCRIPTION, BY REGION, 2023–2030 (THOUSAND UNITS)
  • TABLE 53 NORTH AMERICA: SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 54 NORTH AMERICA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 55 NORTH AMERICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 56 NORTH AMERICA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 57 NORTH AMERICA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 58 NORTH AMERICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 59 US: KEY MACROECONOMIC INDICATORS
  • TABLE 60 US: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 61 US: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 62 US: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 63 US: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 64 US: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 65 CANADA: KEY MACROECONOMIC INDICATORS
  • TABLE 66 CANADA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 67 CANADA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 68 CANADA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 69 CANADA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 70 CANADA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 71 EUROPE: SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 72 EUROPE: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 73 EUROPE: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 74 EUROPE: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 75 EUROPE: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 76 EUROPE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 77 GERMANY: KEY MACROECONOMIC INDICATORS
  • TABLE 78 GERMANY: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 79 GERMANY: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 80 GERMANY: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 81 GERMANY: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 82 GERMANY: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 83 FRANCE: KEY MACROECONOMIC INDICATORS
  • TABLE 84 FRANCE: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 85 FRANCE: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 86 FRANCE: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 87 FRANCE: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 88 FRANCE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 89 UK: KEY MACROECONOMIC INDICATORS
  • TABLE 90 UK: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 91 UK: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 92 UK: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 93 UK: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 94 UK: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 95 ITALY: KEY MACROECONOMIC INDICATORS
  • TABLE 96 ITALY: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 97 ITALY: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 98 ITALY: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 99 ITALY: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION
  • TABLE 100 ITALY: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 101 SPAIN: KEY MACROECONOMIC INDICATORS
  • TABLE 102 SPAIN: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 103 SPAIN: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 104 SPAIN: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 105 SPAIN: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 106 SPAIN: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 107 REST OF EUROPE: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 108 REST OF EUROPE: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 109 REST OF EUROPE: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 110 REST OF EUROPE: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 111 REST OF EUROPE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 114 ASIA PACIFIC: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 118 JAPAN: KEY MACROECONOMIC INDICATORS
  • TABLE 119 JAPAN: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 120 JAPAN: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 121 JAPAN: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 122 JAPAN: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 123 JAPAN: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 124 CHINA: KEY MACROECONOMIC INDICATORS
  • TABLE 125 CHINA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 126 CHINA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 127 CHINA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 128 CHINA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 129 CHINA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 130 INDIA: KEY MACROECONOMIC INDICATORS
  • TABLE 131 INDIA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 132 INDIA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 133 INDIA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 134 INDIA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 135 INDIA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 136 AUSTRALIA: KEY MACROECONOMIC INDICATORS
  • TABLE 137 AUSTRALIA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 138 AUSTRALIA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 139 AUSTRALIA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 140 AUSTRALIA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 141 AUSTRALIA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 142 SOUTH KOREA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 143 SOUTH KOREA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 144 SOUTH KOREA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 145 SOUTH KOREA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 146 SOUTH KOREA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 147 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 148 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 149 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 150 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 151 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 152 LATIN AMERICA: SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 153 LATIN AMERICA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 154 LATIN AMERICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 155 LATIN AMERICA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 156 LATIN AMERICA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 157 LATIN AMERICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 158 BRAZIL: KEY MACROECONOMIC INDICATORS
  • TABLE 159 BRAZIL: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 160 BRAZIL: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 161 BRAZIL: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 162 BRAZIL: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 163 BRAZIL: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 164 MEXICO: KEY MACROECONOMIC INDICATORS
  • TABLE 165 MEXICO: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 166 MEXICO: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 167 MEXICO: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 168 MEXICO: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 169 MEXICO: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 170 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 171 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 172 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 173 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 174 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 175 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 176 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 177 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 178 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 179 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY APPLICATION 2023–2030 (USD MILLION)
  • TABLE 180 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 181 GCC COUNTRIES: SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 182 GCC COUNTRIES: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 183 GCC COUNTRIES: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 184 GCC COUNTRIES: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 185 GCC COUNTRIES: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 186 GCC COUNTRIES: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 187 KINGDOM OF SAUDI ARABIA (KSA): KEY MACROECONOMIC INDICATORS
  • TABLE 188 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 189 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 190 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 191 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 192 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 193 UAE: KEY MACROECONOMIC INDICATORS
  • TABLE 194 UAE: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 195 UAE: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 196 UAE: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 197 UAE: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 198 UAE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 199 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 200 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 201 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 202 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 203 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 204 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 205 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)
  • TABLE 206 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)
  • TABLE 207 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 208 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)
  • TABLE 209 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN SUPPOSITORIES MARKET
  • TABLE 210 SUPPOSITORIES MARKET: DEGREE OF COMPETITION, 2024
  • TABLE 211 SUPPOSITORIES MARKET: REGION FOOTPRINT
  • TABLE 212 SUPPOSITORIES MARKET: TYPE FOOTPRINT
  • TABLE 213 SUPPOSITORIES MARKET: BASE FOOTPRINT
  • TABLE 214 SUPPOSITORIES MARKET: PRESCRIPTION FOOTPRINT
  • TABLE 215 SUPPOSITORIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 216 SUPPOSITORIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 217 SUPPOSITORIES MARKET: PRODUCT APPROVALS, JANUARY 2022–MAY 2025
  • TABLE 218 SUPPOSITORIES MARKET: DEALS, JANUARY 2022–MAY 2025
  • TABLE 219 SUPPOSITORIES MARKET: EXPANSIONS, JANUARY 2022–MAY 2025
  • TABLE 220 SANDOZ GROUP AG: COMPANY OVERVIEW
  • TABLE 221 SANDOZ GROUP AG: PRODUCTS OFFERED
  • TABLE 222 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
  • TABLE 223 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
  • TABLE 224 CIPLA: COMPANY OVERVIEW
  • TABLE 225 CIPLA: PRODUCTS OFFERED
  • TABLE 226 SANOFI: COMPANY OVERVIEW
  • TABLE 227 SANOFI: PRODUCTS OFFERED
  • TABLE 228 SANOFI: DEALS, JANUARY 2022–MAY 2025
  • TABLE 229 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
  • TABLE 230 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
  • TABLE 231 SUN PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022–MAY 2025
  • TABLE 232 BAYER AG: COMPANY OVERVIEW
  • TABLE 233 BAYER AG: PRODUCTS OFFERED
  • TABLE 234 BAYER AG: EXPANSIONS, JANUARY 2022–MAY 2025
  • TABLE 235 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 236 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 237 NOVARTIS AG: DEALS, JANUARY 2022–MAY 2025
  • TABLE 238 ZYDUS GROUP: COMPANY OVERVIEW
  • TABLE 239 ZYDUS GROUP: PRODUCTS OFFERED
  • TABLE 240 ZYDUS GROUP: PRODUCT APPROVALS, JANUARY 2022–MAY 2025
  • TABLE 241 BLISS?GVS PHARMA LIMITED: COMPANY OVERVIEW
  • TABLE 242 BLISS?GVS PHARMA LIMITED: PRODUCTS OFFERED
  • TABLE 243 CHURCH & DWIGHT CO., INC.: COMPANY OVERVIEW
  • TABLE 244 CHURCH & DWIGHT CO., INC.: PRODUCTS OFFERED
  • TABLE 245 BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW
  • TABLE 246 BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED
  • TABLE 247 ADCOCK INGRAM: COMPANY OVERVIEW
  • TABLE 248 ADCOCK INGRAM: PRODUCTS OFFERED
  • TABLE 249 ASPEN HOLDINGS: COMPANY OVERVIEW
  • TABLE 250 ASPEN HOLDINGS: PRODUCTS OFFERED
  • TABLE 251 JULPHAR: COMPANY OVERVIEW
  • TABLE 252 JULPHAR: PRODUCTS OFFERED
  • TABLE 253 HALEON GROUP OF COMPANIES: COMPANY OVERVIEW
  • TABLE 254 HALEON GROUP OF COMPANIES: PRODUCTS OFFERED
  • TABLE 255 LES LABORATOIRES SERVIER: COMPANY OVERVIEW
  • TABLE 256 LES LABORATOIRES SERVIER: PRODUCTS OFFERED
  • TABLE 257 PRESTIGE CONSUMER HEALTHCARE: COMPANY OVERVIEW
  • TABLE 258 PRESTIGE CONSUMER HEALTHCARE: PRODUCTS OFFERED
  • TABLE 259 VIATRIS INC.: COMPANY OVERVIEW
  • TABLE 260 VIATRIS INC.: PRODUCTS OFFERED
  • TABLE 261 GALEN LIMITED: COMPANY OVERVIEW
  • TABLE 262 GALEN LIMITED: PRODUCTS OFFERED
  • TABLE 263 MERIDIAN ENTERPRISES PVT. LTD.: COMPANY OVERVIEW
  • TABLE 264 MERIDIAN ENTERPRISES PVT. LTD.: PRODUCTS OFFERED
  • TABLE 265 COSETTE PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 266 FLAGSHIP: COMPANY OVERVIEW
  • TABLE 267 OUBARI PHARMA: COMPANY OVERVIEW
  • TABLE 268 LAVINA PHARMACEUTICALS PVT. LTD.: COMPANY OVERVIEW
  • TABLE 269 NORWELL: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 SUPPOSITORIES MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 SUPPOSITORIES MARKET: YEARS CONSIDERED
  • FIGURE 3 SUPPOSITORIES MARKET: RESEARCH DESIGN
  • FIGURE 4 SUPPOSITORIES MARKET: KEY PRIMARY SOURCES
  • FIGURE 5 SUPPOSITORIES MARKET: INSIGHTS FROM PRIMARIES
  • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 8 SUPPOSITORIES MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2024
  • FIGURE 9 SUPPOSITORIES MARKET SIZE ESTIMATION: CAGR ESTIMATION, 2024
  • FIGURE 10 TOP-DOWN APPROACH
  • FIGURE 11 BOTTOM-UP APPROACH
  • FIGURE 12 DATA TRIANGULATION METHODOLOGY
  • FIGURE 13 SUPPOSITORIES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 SUPPOSITORIES MARKET, BY BASE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 SUPPOSITORIES MARKET, BY PRESCRIPTION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 SUPPOSITORIES MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 SUPPOSITORIES MARKET, BY PATIENT TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 18 GEOGRAPHICAL SNAPSHOT OF SUPPOSITORIES MARKET
  • FIGURE 19 INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
  • FIGURE 20 RECTAL SUPPOSITORIES SEGMENT AND US LED NORTH AMERICAN MARKET IN 2024
  • FIGURE 21 RECTAL SUPPOSITORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 22 OLEAGINOUS/LIPOPHILIC BASES SEGMENT TO HAVE LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 23 PRESCRIPTION SUPPOSITORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 24 CHINA TO REGISTER HIGHEST GROWTH IN SUPPOSITORIES MARKET FROM 2025 TO 2030
  • FIGURE 25 SUPPOSITORIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 26 REVENUE SHIFT AND NEW REVENUE POCKETS FOR SUPPOSITORIES MARKET
  • FIGURE 27 AVERAGE SELLING PRICE OF RECTAL SUPPOSITORIES, BY KEY PLAYER, 2025 (USD)
  • FIGURE 28 SUPPOSITORIES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 29 SUPPOSITORIES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 30 SUPPOSITORIES MARKET: INVESTMENT AND FUNDING SCENARIO, 2020–2024
  • FIGURE 31 SUPPOSITORIES MARKET: PATENT ANALYSIS, JANUARY 2014–MAY 2025
  • FIGURE 32 TOP APPLICANT COUNTRIES/REGIONS FOR SUPPOSITORIES PATENTS, JANUARY 2014–MAY 2025
  • FIGURE 33 SUPPOSITORIES MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE
  • FIGURE 35 KEY BUYING CRITERIA, BY TYPE
  • FIGURE 36 AI USE CASES
  • FIGURE 37 NORTH AMERICA: SUPPOSITORIES MARKET SNAPSHOT
  • FIGURE 38 ASIA PACIFIC: SUPPOSITORIES MARKET SNAPSHOT
  • FIGURE 39 REVENUE ANALYSIS OF TOP FIVE PLAYERS IN SUPPOSITORIES MARKET, 2022–2024
  • FIGURE 40 SUPPOSITORIES MARKET SHARE ANALYSIS, 2024
  • FIGURE 41 RANKING OF KEY PLAYERS IN SUPPOSITORIES MARKET, 2024
  • FIGURE 42 SUPPOSITORIES MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 43 EV/EBITDA OF KEY VENDORS
  • FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 45 SUPPOSITORIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 46 SUPPOSITORIES MARKET: COMPANY FOOTPRINT
  • FIGURE 47 SUPPOSITORIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 48 SANDOZ GROUP AG: COMPANY SNAPSHOT (2024)
  • FIGURE 49 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 50 CIPLA: COMPANY SNAPSHOT (2024)
  • FIGURE 51 SANOFI: COMPANY SNAPSHOT (2024)
  • FIGURE 52 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 53 BAYER AG: COMPANY SNAPSHOT (2024)
  • FIGURE 54 NOVARTIS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 55 ZYDUS GROUP: COMPANY SNAPSHOT (2024)
  • FIGURE 56 BLISS?GVS PHARMA LIMITED: COMPANY SNAPSHOT (2024)
  • FIGURE 57 CHURCH & DWIGHT CO., INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 58 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 59 ADCOCK INGRAM: COMPANY SNAPSHOT (2023)
  • FIGURE 60 ASPEN HOLDINGS: COMPANY SNAPSHOT (2023)
  • FIGURE 61 JULPHAR: COMPANY SNAPSHOT (2024)
  • FIGURE 62 HALEON GROUP OF COMPANIES: COMPANY SNAPSHOT (2024)
  • FIGURE 63 LES LABORATOIRES SERVIER: COMPANY SNAPSHOT (2023)
  • FIGURE 64 PRESTIGE CONSUMER HEALTHCARE: COMPANY SNAPSHOT (2024)
  • FIGURE 65 VIATRIS INC.: COMPANY SNAPSHOT (2024)

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, SEC filings of companies and publications from government sources[such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), European Federation of Pharmaceutical Industries and Associations (EFPIA), American Journal of Drug Delivery and Therapeutics, and Parenteral Drug Association (PDA) were referred to identify and collect information for the global suppositories market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends, to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various companies and organizations in the suppositories market. The primary sources from the demand side include hospitals & clinics and home care settings. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

Suppositories Market

Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

Source: MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global suppositories market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was made for the major players (who contribute at least 70–75% of the market share at the global level). Also, the suppositories market was split into various segments and sub-segments based on:

  • List of major players operating in the suppositories market at the regional and/or country level
  • Product mapping of various suppositories manufacturers at the regional and/or country level
  • Mapping of annual revenue generated by listed major players from suppository products (or the nearest reported business unit/product category)
  • Revenue mapping of major players to cover at least 70–75% of the global market share as of 2024
  • Extrapolation of the revenue mapping of the listed major players to derive the global suppositories market value of the respective segments/subsegments
  • Summation of the market value of all segments/subsegments to arrive at the global suppositories market  

Market Size Estimation (Bottom-up and Top-down Approach)

Suppositories Market

Data Triangulation

After arriving at the overall size of the global suppositories market through the methodology mentioned above, this market was split into several segments and subsegments. Where applicable, the data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.

Market Definition

Suppositories are solid dosage forms designed to deliver medications by insertion into body orifices, most commonly the rectum, vagina, or urethra, where they dissolve or melt at body temperature to release the active pharmaceutical ingredient. Typically composed of a gelatin or cocoa butter base, suppositories enable local or systemic therapeutic effects and are particularly useful when oral administration is not feasible.

Stakeholders

  • Suppository Manufacturers
  • Suppository Distributors
  • Healthcare Providers
  • Government Regulatory Authorities
  • Contract Manufacturers & Third-party Suppliers
  • Research Laboratories & Academic Institutes
  • Clinical Research Organizations (CROs)
  • Pharmacies & Retailers
  • Raw Material & Excipient Suppliers
  • Market Research & Consulting Firms

Report Objectives

  • To define, measure, and describe the global suppositories market by type, base, prescription, application, patient type, and region
  • To provide detailed information about the significant factors influencing the suppositories market growth (drivers, restraints, challenges, and opportunities)
  • To strategically analyze the regulatory, pricing, value chain, supply chain, ecosystem, technology, Porter’s Five Forces, and patent analysis
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of market segments in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To strategically analyze the market structure, profile the key players in the global suppositories market, and comprehensively analyze their core competencies
  • To track and analyze company developments such as, partnerships, expansions, and product launches & approvals in the suppositories market
  • To track and analyze competitive developments such as mergers & acquisitions, product developments, partnerships, agreements, collaborations, and expansions in the global suppositories market

 

Previous Versions of this Report

"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Suppositories Market

DMCA.com Protection Status